Researchers tested a cutting-edge cancer treatment called CAR-T cell therapy for advanced liver cancer. This approach genetically modifies a patient's immune cells to better recognize and attack cancer cells that display a specific protein called GPC3, commonly found on liver tumors. The phase I trial enrolled 10 patients to evaluate whether this personalized immunotherapy was safe and showed early signs of effectiveness. While the study was terminated early, it represents an important step in developing targeted treatments for hepatocellular carcinoma, the most common type of liver cancer and a leading cause of cancer deaths worldwide.
